Our mission is to enhance the survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts.

What’s in the Patient Section?

What’s in the Powered Section?

What’s in the Science section?

What’s in the For Life Section?

Real World Evidence In Action

Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.

GIST Collaborative Tissue Bank
GIST Trials Database
The Life Raft Group Patient Registry
SideEQ
Project Surveillance

RECENT LRG DATA

0
Patients in LRG Registry
0%
of Patient Registry members know their mutation
0
Total # of Tissue
0%
of LRG members know their Risk of Recurrence

Update your Patient Registry Information.

Update

Join The Life Raft Group.

Join Our Community

Available GIST clinical trials.

Learn About Trials

Search our database of GIST Specialists.

View Specialists
Dr. Monica Anderson

Dr. Monica Anderson

Diagnosed in 2012 with Adult GIST.

Marc Wasserman

Marc Wasserman

Diagnosed in 2006 with Adult GIST.

Bella Rocco

Bella Rocco

Diagnosed in 2009 with Pediatric
(SDH-Deficient) GIST.

HELP US SAVE LIVES

The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.

SHARE YOUR DATA
DONATE TO THE LRG
VOLUNTEER YOUR TIME
CONTRIBUTE YOUR TISSUE
  • LRG Science Thumbnail

First-Line Imatinib More Effective Than Widely Believed – LRG Science

The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

  • Ayvakit logo

Breaking News for GIST Patients – Avapritinib Approved!

By |January 9th, 2020|

Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

  • CTOS Japan

CTOS 2019 Highlights

By |December 20th, 2019|

CTOS, "The Connective Tissue Oncology Society", is an organization of medical specialists and researchers who specialize in bone and soft tissue tumors. They hold a meeting every year to discuss the latest innovations in this area. This year the meeting took place in Tokyo from November 13 until 16.

GIST Day of Learning in Seattle

GDOL Seattle 2020

February 15 @ 9:00 AM - 5:00 PM

GDOL 2019 Tampa

GDOL Tampa 2020

March 28 @ 9:00 AM - 5:00 PM

Keep up with the latest news, events, and opportunities to help.

Subscribe

To contact The Life Raft Group, please call 973-837-9092

GLOBAL PARTNERS